SCHEMBL4921962

SCHEMBL4921962

CN(C)[C@@H]1CCN(c2ccc(-n3ncc4c(Nc5ccccc5Cl)ncnc43)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.52
TP53 P04637 8/20 0.51
LMNA P02545 6/20 0.51
HTT P42858 4/20 0.50
HSD17B10 Q99714 4/20 0.50
RAB9A P51151 4/20 0.50
TSHR P16473 3/20 0.50
NPC1 O15118 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
KDM4E B2RXH2 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPSR1 Q6W5P4 2/20 0.46
PIP4K2A P48426 1/20 0.45
GAA P10253 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
INSR P06213 1/20 0.45
IGF1R P08069 1/20 0.45
ALK Q9UM73 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927126 1.00 MAPT (0.52) MAPTTP53LMNAHTTHSD17B10
SCHEMBL4921977 1.00 MAPT (0.52) MAPTTP53LMNAHTTHSD17B10
SCHEMBL4926381 0.90 TP53 (0.65) MAPTTP53LMNAHTTHSD17B10
SCHEMBL4921954 0.90 TP53 (0.65) MAPTTP53LMNAHTTHSD17B10
SCHEMBL4921937 0.90 TP53 (0.65) MAPTTP53LMNAHTTHSD17B10
SCHEMBL4921866 0.89 MAPT (0.50) MAPTTP53LMNAHTTRAB9A
SCHEMBL4925278 0.89 MAPT (0.50) MAPTTP53LMNAHTTRAB9A
SCHEMBL4921849 0.89 MAPT (0.50) MAPTTP53LMNAHTTRAB9A
SCHEMBL4927701 0.86 MAPT (0.55) MAPTTP53LMNAHTTHSD17B10
SCHEMBL4939562 0.86 MAPT (0.55) MAPTTP53LMNAHTTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US claimed
EP-1812441-A1 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS Novartis AG (CH) 2007-08-01 EP claimed
WO-2006050946-A1 1,4 SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-05-18 WO claimed
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors NOVARTIS AG (CH) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096868-A1 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors MAP3K1, MAP4K2, MAP4K5 MAPT 1638/4885TP53 849/4885LMNA 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.